News | July 27, 2011

FDA Advisory Panel Recommends Approval of Excor Pediatric Ventricular Assist Device

July 27, 2011 – A special panel convened July 21 in Gaithersburg, Md., to review the results of the Excor pediatric ventricular assist device (VAD) investigational device exemption (IDE) clinical trial. The panel convened at the request of Bram Zuckerman, M.D., director, division of cardiovascular devices, Center for Devices and Radiologic Health of the U.S. Food and Drug Administration (FDA).

The specific charge of the panel was to review the clinical data from the trial and to make recommendations to the FDA concerning the safety and probable benefit of the Excor as it pertains to an application for humanitarian device exemption (HDE) approval. This 22-member panel was composed of a group of experts in pediatric and adult cardiology, pediatric and adult cardiac surgery, neurology, biostatistics and other areas of expertise. It also included patient, consumer and industry representatives. The panel was chaired by Clyde Yancy, M.D., chief of the division of cardiology, Northwestern University School of Medicine in Chicago.

In preparation for presenting the study results to the panel, a team representing Berlin Heart and the investigation was assembled. Working together over several months, including several face-to-face meetings, this group, now referred to as the Berlin Heart "Dream Team," worked very hard to be well prepared. The main presentation and the bulk of the clinical data and trail results was presented to the panel by the national principal investigator of the study, Charles D. Fraser, Jr., M.D., FACS, surgeon-in-chief, congenital heart surgery, Texas Children's Hospital and professor of surgery and pediatrics, Baylor College of Medicine; and Charles E. Canter, M.D., medical director, Heart Failure/Transplant Program of St. Louis Children's Hospital, and professor of pediatrics, Washington University School of Medicine.

The events of the day culminated in the public forum vote by the panel on the questions of Excor device safety and probable benefit. The panel members voted unanimously in favor of HDE approval.

The following U.S. centers participated in the IDE study:

  • Arkansas Children's Hospital (Ark.)
  • Boston Children's Hospital (Mass.)
  • Children's Healthcare of Atlanta (Ga.)
  • Children's Hospital of Wisconsin (Wis.)
  • The Children's Hospital of Denver (Colo.)
  • Lucille Packard Children's Hospital at Stanford (Calif.)
  • Mott Children's Hospital (Mich.)
  • Mount Sinai Hospital (N.Y.)
  • Pittsburgh Children's Hospital (Penn.)
  • Riley Children's Hospital (Ind.)
  • Seattle Children's Hospital (Wash.)
  • St. Louis Children's Hospital (Mo.)
  • Texas Children's Hospital (Texas)
  • Children's Hospital at the University of Alabama (Ala.)
  • University of Minnesota at Fairview (Minn.)

While Berlin Heart awaits the final decision of the FDA, implants of the Berlin Heart Excor pediatric VAD in the United States for bridge-to-transplant patients are continuing under a continued access protocol approved by the FDA.

For more information:


Related Content

Leviticus Cardio and Jarvik Heart Unveil Wireless Heart Pump System
News | Ventricular Assist Devices (VAD) | February 11, 2019
Heart failure experts at the National Research Center for Cardiac Surgery in Astana, Kazakhstan, recently announced the...
Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Overlay Init